Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Joseph Merchant (NPI 1699765826)

Field	Value
Entity Type	Individual
Organization	Joseph Merchant
Address	1111 Duff Ave
City	Ames
State	IA
ZIP	50010
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 27, 2005

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

Clinical profile and service mix align with hematology/oncology practice patterns: the provider’s top revenue code is J9271 (pembrolizumab) and the claims mix includes multiple chemotherapy administration codes (96413, 96365, 96417) and supportive oncology drugs, indicating an infusion-centric ambulatory oncology operation rather than a purely consultative practice. This drug- and infusion-focused mix is consistent with the provider taxonomy Hematology & Oncology Physician and the large share of drug revenue in the Medicare portfolio.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 71.4% of the provider’s Medicare revenue, with J9271 alone contributing $885.8K (52.8% of Total Medicare revenue: $1.8M). The next two drivers are J0897 at $192.7K (11.5%) and J1561 at $119.7K (7.1%), showing that a small set of biologic and specialty drug codes dominate Medicare receipts.

This provider is effectively single-payer in the public program context: Total Medicare revenue: $1.8M while Total Medicaid revenue: none (no Medicaid billing on file), so there is no Medicaid footprint to diversify public-payer exposure. Reliance on Medicare means the practice’s public-revenue base is concentrated with one payer program rather than split across Medicare and Medicaid populations.

Competitive standing varies by code: for the top drug J9271 the provider ranks #365 of 1841 nationally (80th percentile; typical, unremarkable volume for this code), indicating solid but not dominant national standing in pembrolizumab administration. For J0897 the provider ranks #1121 of 10057 (89th percentile; typical, unremarkable volume), signaling relatively high activity in denosumab versus peers, while J1561 ranks #100 of 180 (44th percentile; typical, unremarkable volume), which is only modest within its smaller comparison group.

Office visit and E/M activity is unusually high versus peers: 99214 shows 942 claims and $85.7K revenue and ranks #13263 of 479517 (97th percentile; notably above typical national volume for this code), while 99213 shows 1.1K claims and $70.6K revenue and ranks #4660 of 457151 (99th percentile; extreme outlier, far above typical national volume for this code). These high percentiles for established-patient visits suggest a substantial ambulatory patient panel and frequent follow-up encounters in addition to infusion services.

Tenure data indicate established presence: NPI enumerated 2005-10-27 (~21 years ago), which supports interpretation of sustained practice operations and the accumulation of the reported Medicare revenue over a long period. Long enrollment can reflect an ongoing patient base and established referral relationships that support recurring infusion and follow-up visit volumes.

Operational implications: the practice’s heavy dependence on a few high-revenue biologic drugs (notably J9271) means revenue is sensitive to utilization patterns and drug reimbursement dynamics for those specific agents. Combined with the absence of Medicaid billing, this concentration suggests limited public-payer diversification and potential vulnerability to shifts in Medicare coverage, reimbursement policy, or changes in prescribing patterns for the dominant agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

95 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,600	$40	$885.8K
J0897	Injection, denosumab, 1 mg	10,140	$20	$192.7K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	3,150	$40	$119.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	940	$90	$85.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,140	$60	$70.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	590	$90	$55.1K
J1439	Injection, ferric carboxymaltose, 1 mg	41,250	$1	$41.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	20,620	$1	$41.2K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	280	$90	$24.3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	130	$130	$17.8K

Showing 1–10 of 95

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 95 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

Joseph Merchant — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

95 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	30	17,200	$40	$902.3K
J1561	4	10	4,150	$40	$170.9K
J0897	17	190	1,920	$20	$74.1K
J0881	5	10	15,520	$1	$43.2K
J1439	6	10	41,250	$1	$39.7K
J2506	14	20	440	$80	$38.9K
96413	6	80	210	$90	$24K
J9217	29	50	140	$130	$23.4K
91320	366	460	90	$130	$20K
91322	387	580	80	$140	$15.2K

Showing 1–10 of 95

Related Providers

Other providers that share a Tax Identification Number (TIN) with Joseph Merchant, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dallas County Hospital District	TX	General Acute Care Hospital	$0	$152.8M
Mcfarland Clinic PC	IA	Multi-Specialty Clinic/Center	$0	$26.7M
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Greene County Medical Center	IA	Rural Health Clinic/Center	$0	$7.7M
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Dallas County Hospital	IA	Rural Health Clinic/Center	$0	$5.2M

Nearby Providers

Other providers in the same ZIP code as Joseph Merchant, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mainstream Living, Inc.	IA	Social Worker	$0	$134.3M
Youth And Shelter Services, Inc.	IA	Counselor	$0	$11.4M
Mary Greeley Medical Center	IA	General Acute Care Hospital	$0	$9.1M
Mary Greeley Medical Center	IA	Land Ambulance	$0	$4.4M
Venkatesh Rudrapatna	IA	Hematology & Oncology Physician	$3.4M	$0
Sreenath Kodali	IA	Hematology & Oncology Physician	$3.2M	$0
The Richmond Center	IA	Mental Health Counselor	$0	$2.4M
Sonam Patel	IA	Hematology & Oncology Physician	$1.8M	$0
Tracy Kangas	IA	Ophthalmology Physician	$1.1M	$0
Steven Anderson	IA	Ophthalmology Physician	$755.9K	$0

Joseph Merchant — Billing Profile & Reimbursement Data

Sign up for Joseph Merchant — Billing Profile & Reimbursement Data policy alerts

Joseph Merchant — Billing Profile & Reimbursement Data

Sign up for Joseph Merchant — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References